A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain

Palliative Medicine

Volumn 18, Issue 1, 2004, Pages 19-24

  Riley, Julia ^a   Ross, J R ^a   Rutter, D ^a   Shah, S ^a   Gwilliam, B ^a   Wells, A U ^b   Welsh, K ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Alternative opioids; Cancer pain; Morphine; Morphine intolerance; Opioid switching

Indexed keywords

ALKALINE PHOSPHATASE; CYTOTOXIC AGENT; MORPHINE; OPIATE; SERUM ALBUMIN;

AGE; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALGESIA; ARTICLE; CANCER CLASSIFICATION; CANCER PAIN; CANCER PATIENT; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PAIN ASSESSMENT; PRACTICE GUIDELINE; PREDICTION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; WORLD HEALTH ORGANIZATION;

AGED; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHRONIC DISEASE; HEMATOLOGIC DISEASES; HUMANS; LEUKOCYTES; MORPHINE; NEOPLASMS; PAIN, INTRACTABLE; RETROSPECTIVE STUDIES;

EID: 1242296180     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/0269216304pm856oa     Document Type: Article

References (23)

1. World Health Organization. Cancer pain relief, second edition. Geneva, Switzerland: World Health Organization, 1996.
2. Expert Working Group of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84: 587-93.
3. Hanks GW, Forbes K. Opioid responsiveness. Acta Anaesth Scand 1997; 41: 154-58.
4. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995; 76: 1283-93.
5. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
6. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378-84.
7. Mercandante S, Portenoy RK. Opioid Poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001; 21: 144-50.
8. Faura CC, Moore RA, Horga JF, Hand CW, McQuay HJ. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage 1996; 11: 95-102.
9. Hunt A, Joel S, Dick G, Goldman A. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. J Pediatr 1999; 135: 47-55.
10. Van Crutgen JT, Somogyi AA, National RL, Reynolds G. The effect of old age on the disposition and nociceptive response of morphine and norphine-6-glucuronide in the rat. Pain 1997; 71: 199-205.
11. Globerson A, Effros R. Aging of lymphocytes and lymphocytes in the aged. Rev Immunol Today 2000; 21: 515-21.
12. Einstein TK, Hilburger ME. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations J Neuroimmunol 1998; 83: 36-44.
13. Maltoni M, Pirovano M, Nanni O, et al. Biological indices predictive of survival in 519 Italian terminally ill cancer patients. J Pain Symptom Manage 1997; 13: 1-9.
14. Daniel R, Mellon B, Bayer M. Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity. Brain Res 1998; 789: 56-67.
15. Suzuki S, Miyagi T, Chuang TK, Chuang LF, Doi RH, Chuang RY. Morphine upregulates mu opioid receptors of human and monkey lymphocytes. Biochem Biophys Res Commun 2000; 279: 621-28.
16. Bryant HU, Bernton EW, Holaday JW. Immunosuppressive effects of chronic morphine treatment in mice. Life Sci 1987; 41: 1731-38.
17. Gungor M, Genc E, Sogduyu H, Eroglu L, Koyuncuoglu H. Effects of chronic administration of morphine on primary immune response in mice. Experientia 1980; 36: 1309-10.
18. Mehrishi JN, Mills I. Opioid receptors on lymphocytes and platelets in man. Clin Immunol Immunopathol 1983; 27: 240-49.
19. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine 6 glucuronide. BMJ 1986; 292: 1548-49.
20. McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: influences on morphine and metabolite concentrations. Clin Pharm Ther 1990; 48: 236-44.
21. Morgan DJ, Mclean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 1995; 29: 370-91.
22. Rodigheiro V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 2000; 38: 491.
23. Kotb HI, el-Kabsh MY, Emara SE, Fouad EA. Pharmacokinetics of controlled released morphine (MST) in patients with liver cirrhosis. Br J Anaesth 1997; 79: 804-806.